| The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein PJ Lu, G Wulf, XZ Zhou, P Davies, KP Lu Nature 399 (6738), 784-788, 1999 | 983 | 1999 |
| Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA A Ryo, F Suizu, Y Yoshida, K Perrem, YC Liou, G Wulf, R Rottapel, ... Molecular cell 12 (6), 1413-1426, 2003 | 871 | 2003 |
| PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer C Pantelidou, O Sonzogni, M De Oliveria Taveira, AK Mehta, A Kothari, ... Cancer discovery 9 (6), 722-737, 2019 | 700 | 2019 |
| Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c‐Jun towards cyclin D1 GM Wulf, A Ryo, GG Wulf, SW Lee, T Niu, V Petkova, KP Lu The EMBO journal, 2001 | 682 | 2001 |
| Pin1 regulates turnover and subcellular localization of β-catenin by inhibiting its interaction with APC A Ryo, M Nakamura, G Wulf, YC Liou, KP Lu Nature cell biology 3 (9), 793-801, 2001 | 644 | 2001 |
| PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells WJ Israelsen, TL Dayton, SM Davidson, BP Fiske, AM Hosios, G Bellinger, ... Cell 155 (2), 397-409, 2013 | 628 | 2013 |
| The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-β production L Pastorino, A Sun, PJ Lu, XZ Zhou, M Balastik, G Finn, G Wulf, J Lim, ... Nature 440 (7083), 528-534, 2006 | 618 | 2006 |
| Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer A Juvekar, LN Burga, H Hu, EP Lunsford, YH Ibrahim, J Balmañà, ... Cancer discovery 2 (11), 1048-1063, 2012 | 508 | 2012 |
| The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response H Zheng, H You, XZ Zhou, SA Murray, T Uchida, G Wulf, L Gu, X Tang, ... Nature 419 (6909), 849-853, 2002 | 504 | 2002 |
| TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes NM Tung, ME Robson, S Ventz, CA Santa-Maria, R Nanda, PK Marcom, ... Journal of Clinical Oncology 38 (36), 4274-4282, 2020 | 477 | 2020 |
| Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer S Vinayak, SM Tolaney, L Schwartzberg, M Mita, G McCann, AR Tan, ... JAMA oncology 5 (8), 1132-1140, 2019 | 452 | 2019 |
| Phosphoinositide 3-kinase regulates glycolysis through mobilization of aldolase from the actin cytoskeleton H Hu, A Juvekar, CA Lyssiotis, EC Lien, JG Albeck, D Oh, G Varma, ... Cell 164 (3), 433-446, 2016 | 436 | 2016 |
| PIN1 Is an E2F Target Gene Essential for Neu/Ras-Induced Transformation of Mammary Epithelial Cells A Ryo, YC Liou, G Wulf, M Nakamura, SW Lee, KP Lu Molecular and cellular biology 22 (15), 5281-5295, 2002 | 365 | 2002 |
| The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer G Ayala, D Wang, G Wulf, A Frolov, R Li, J Sowadski, TM Wheeler, KP Lu, ... Cancer research 63 (19), 6244-6251, 2003 | 358 | 2003 |
| Phosphorylation-specific prolyl isomerization: is there an underlying theme? G Wulf, G Finn, F Suizu, KP Lu Nature cell biology 7 (5), 435-441, 2005 | 311 | 2005 |
| Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage GM Wulf, YC Liou, A Ryo, SW Lee, KP Lu Journal of Biological Chemistry 277 (50), 47976-47979, 2002 | 309 | 2002 |
| Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial PA Konstantinopoulos, WT Barry, M Birrer, SN Westin, KA Cadoo, ... The Lancet Oncology 20 (4), 570-580, 2019 | 287 | 2019 |
| Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer A Ryo, YC Liou, KP Lu, G Wulf Journal of cell science 116 (5), 773-783, 2003 | 282 | 2003 |
| Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy PK Morrow, GM Wulf, J Ensor, DJ Booser, JA Moore, PR Flores, Y Xiong, ... Journal of Clinical Oncology 29 (23), 3126-3132, 2011 | 266 | 2011 |
| Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation Y Xing, NU Lin, MA Maurer, H Chen, A Mahvash, A Sahin, A Akcakanat, ... Breast Cancer Research 21 (1), 78, 2019 | 259 | 2019 |
Kun Ping LuWestern UniversityVerified email at uwo.ca
